MAP2K7 and neoplasm: The authors’ research further indicates that inhibiting key factors of the MAPK pathway, such as MEK, can increase the immunogenicity of tumor cells leading to the upregulation of MHC-I (major histocompatibility complex class-I) expression and increased mRNA levels of IFN-γ, IL-6, IL-1B, and TNF-α.